Table 3.
Incidences of class-1, class-2 and class-3 BRAF mutations
| BRAF | Class-1 | p.V600E | p.V600K | Class-2 | Class-3 | Unclassified | |
|---|---|---|---|---|---|---|---|
| Uveal (n = 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mucosal (n = 20) | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Cutaneous (n = 286) | 132 (46%) | 105 (37%)a | 82 (29%) | 20 (7.0%) | 10 (3.5%) | 14 (4.9%) | 3 |
| H/N/UB (n = 98) | 44 (45%) | 28 (29%) | 14 (14%) | 14 (14%) | 5 (5.1%) | 10 (10%) | 1 |
| non-H/N/UB (n = 188) | 88 (47%) | 77 (41%)a | 68 (36%) | 6 (3.2%) | 5 (2.7%) | 4 (2.1%) | 2 |
| Others (n = 138)b | 56 (41%) | 42 (30%) | 35 (25%) | 7 (5.1%) | 4 (2.9%) | 7 (5.1%) | 4 |
| Total (n = 446) | 189 (42%) | 147 (33%) a | 117 (26%) | 27 (6.1%) | 14 (3.1%) | 22 (4.9%) | 7 (1.6%) |
H/N/UB: Primary tumors at head, neck or upper back
aIncluding 3 tumors with p.V600R
bMetastatic melanomas of unknown origin or without information of the primary site, including one tumor with p.S605I and p.V600E within the same allele